Keros Therapeutics Inc. (KROS): Price and Financial Metrics
KROS Price/Volume Stats
| Current price | $56.24 | 52-week high | $73.00 |
| Prev. close | $55.19 | 52-week low | $27.02 |
| Day low | $55.21 | Volume | 311,700 |
| Day high | $57.60 | Avg. volume | 417,119 |
| 50-day MA | $63.50 | Dividend yield | N/A |
| 200-day MA | $44.17 | Market Cap | 2.03B |
KROS Stock Price Chart Interactive Chart >
Keros Therapeutics Inc. (KROS) Company Bio
Keros Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on treatments for rare muscle diseases. The company was founded in 2015 and is headquartered in Lexington, MA.
Latest KROS News From Around the Web
Below are the latest news stories about KEROS THERAPEUTICS INC that investors may wish to consider to help them evaluate KROS as an investment opportunity.
Keros Therapeutics prices upsized stock offering to raise $140 millionMore on Keros Therapeutics |
HollySys Automation, Keros Therapeutics, and More Stocks See Action From Activist InvestorsActivists report to the SEC on HireRight Holdings, HollySys Automation Technologies, Rover Group, Keros Therapeutics, and Beacon Roofing Supply |
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and ExpositionKER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burdenDurable clinical responses were associated with improvements in patient-reported measures of fatigueBiomarker data demonstrate that KER-050 treatment has potential to reduce NT-proBNP a measure of cardiac stressPreliminary findings from ongoing Phase 2 clinical trial in myelofibrosis demonstrate that KER-050 can not only ameliorate ineffective hematopoiesis and add |
Keros Therapeutics to Present at Upcoming Healthcare ConferencesLEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare |
KROS Price Returns
| 1-mo | -14.93% |
| 3-mo | -1.78% |
| 6-mo | 103.33% |
| 1-year | 29.32% |
| 3-year | -11.92% |
| 5-year | N/A |
| YTD | 41.45% |
| 2023 | -17.20% |
| 2022 | -17.93% |
| 2021 | -17.05% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...